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INTRODUCTION 
Cervical cancer is the second most common cancer among females 
and is the first cause of cancer related deaths in developing countries. In 
urban areas, it accounts for 40% and 60% in rural areas.(cancer registry 
barshi) 1 in 154 deaths occur in the world due to carcinoma cervix(cancer 
statistics 2014). Key to prevent cervical cancer is awareness. Increased 
incidence in India due to lack of knowledge and it cannot happen to me 
attitude. 
In those countries where effective screening, diagnosis and 
treatment is limited or absent, burden of cervical cancer is highest. 
Cervical cancer mostly hits the young population, whose lives seem 
shattered after they come to know of it. 
1 out of 4 women die due to cervical cancer in the world is an 
Indian. New cases diagnosed in India per year is 1,40,000. More than 20 
women die every day.8women die every hour. A women die every 
7mins.(FERY ET AL IN GLOBOCAN 2008). 
It is very important to find the effective screening method, so that 
the disease can be diagnosed earlier which helps to bring down the 
mortality and morbidity due to cervical cancer. 
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In developed countries, pap smear has brought down the incidence of 
cervical cancer. Better information can be provided by AgNOR, a 
molecular tumour marker which stands for silver stained (Ag) nucleolar 
organizer regions(NORs). 
 
NORs denotes the loop of ribosomal DNA which transcribe to 
RNA. They are the tools used to study the proliferating capacity of the 
cell as they are related to cell cycle[1].Ionic silver precipitates at carboxyl 
and sulphydryl groups to form argyrophilic proteins. After silver staining 
NORs can be identified as black dots localised throughout the nucleolar 
area. 
 
There are various number of clinical and histological parameters 
available for determining the aggressiveness of the tumour.DNA content, 
Ki-67, sphase fraction, oncogenes, AgNOR are some of the parameters. 
AgNOR is a simple, cost effective, quick and reliable adjuvant to 
histopathology. 
 
AgNOR count was found to be more in malignant than in normal 
cells. It is used to deliniate the doubtful cases of CIN. It is also used as a 
prognostic tool. 
 
Studies carried out in different tumour types demonstrated that 
malignant cells shows a greater protein than non malignant cells. 
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Study of AgNOR may become an important parameter to determine the 
aggressiveness of tumour at places where costly methods are not 
available.[2] 
 
AgNOR size and number denotes the nucleolar and cell 
proliferative activity. Its distribution in the nucleus is useful in tumour 
detection and prognosis.Various studies are currently available to explore 
the possibility of finding out the tumour marker potential of AgNOR 
dots.There exists a relationship between AgNOR pleomorphism and 
neoplastic development in the uterine cervix.The correlation exists 
between HPV infection and AgNOR pleomorphism.AgNOR counts can 
replace  HPV DNA testing to discover high risk SIL cases.(CANCER 
MEDICAL SCIENCE JOURNAL 2013). 
 
AgNOR is able to pick up grey zones between benign and 
malignant. Eventhough pap smear is the universal test for 
screening,single conventional pap smear is unable to detect 40-50%of 
biopsy confirmed HSIL and invasive cervical cancers. AgNOR count is 
useful in doubtful cases, especially when cervical smears shows 
inflammatory features or metaplasia.(Lynette denny BJOG 2005). 
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In this study, AgNOR counts of cervical lesions are compared with 
those of HPE and results are analyzed for statistically significant 
difference in different groups. 
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AIM OF STUDY 
 
1. Women with abnormal ymptoms and abnormal cervix are subjected to 
cervical biopsy and histopathological diagnosis done with H & E stain 
and AgNOR scoring with silver stain. 
2. To correlate histopathological results and AgNOR counts of cervical 
lesions. 
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REVIEW OF LITERATURE 
 
 Cell cycle is the ordered set of events resulting in cell growth and its 
division. 
 G0- This is the phase where a cell quits dividing and it is the 
temporary resting period. 
 G1-In this phase, cells increase in size, produce RNA and synthesise 
protein. This ensures that everything is ready for DNA synthesis. 
 S-DNA replication occurs in this phase. The complete DNA 
instructions in the cell must be duplicated to produce two similar 
daughter cells. 
 G2-In this phase, cell continue to grow and produce new proteins. 
 M-Cell growth stop at this stage. Cell is orderly divided into two 
similar daughter cells 
 NORs located on the short arm of chromosomes 13,14,15,21,22[3,4] 
 NORs are clearly demonstrated in metaphase. 
 DNA content at the end of S phase is an indicator of proliferative 
activity. AgNOR detects the DNA content at this stage. 
 AgNORs is known to increase with increase in cell ploidy, 
transcriptional activity and in states of active cell proliferation. 
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Stages of Cell Cycle 
 
 Transition from one phase to another regulated by different cellular 
proteins.they are the cyclins and cyclin dependent kinases.cyclins are 
required to end mitosis in a cell cycle. 
 AgNORs in oncology workshop held in Berlin in 1993 first identified 
the guidelines for AgNOR protein evaluation. 
 Interest in AgNOR proteins increased greatly around the end of 1980s. 
(DEREZINI ET AL 1994). 
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AgNOR IN ONCOLOGY: 
Guski et al proved that AgNOR count among the malignant cases 
is significantly higher than benign .They demonstrated that total AgNOR 
number and area increase from atypical ductal hyperplasia to ductal 
carcinoma in situ in breast cancer.[5] 
 
 Rivera et al analyzed the number and distribution pattern of NORs 
by silver staining in the samples that combined a model of chemical 
carcinogenesis and chronic stress[6] 
 
AgNOR is used as a major and independent prognostic factor in 
surgically treated colorectal cancer. This study emphasized the efficiency 
of the predictive power of AgNOR with regard to chemotherapy[7] 
 
Gupta et al in 2013 demonstrated that AgNOR parameters are 
useful indicators to evaluate the malignant behaviour of Gall bladder 
carcinoma. AgNOR predicts the response of the tumour to treatment and 
detects residual viable tumour.[8]Nishizawa et al reported that an increased 
number and size of AgNOR dots associated with lymphnode metastasis 
and shorter survival of patients who had undergone surgical resection of 
gall bladder cancers.[9] 
 
 9 
 
AgNOR technique is an efficient and practical tool to distinguish 
mesothelium from neoplastic cells. It is also useful as a prognostic 
markers of survival in squamous cell carcinoma of lung. Bernardi et al 
are interested to determine the prognostic markers from routine 
histopathological and cytological material by H&E and AgNOR stained 
preparations.[10] 
 
AgNOR count is used as an adjunct and provides a significant cell 
kinetic evaluation of prognostic lesions. Nakamura et al analyzed by his 
study that there occurs a statistically significant difference between 
benign and malignant lesions in AgNOR count.[11] 
 
Pollock studied the correlation of NORs in exocrine pancreas, 
chronic pancreatitis and adenocarcinoma. It is definitely useful in 
differentiating various pancreatic lesions.[12] 
 
Mulazim demonstrated that AgNOR count,its size and dispersion   
was proved to be an important marker in grading astrocytic lesions.[13] 
 
  Yamanoto studied AgNOR in Renal cell carcinoma and its 
efficacy as a marker of proliferative activity.AgNOR values were found 
to be higher than those in normal tubules and NORs increased with the 
progress of grades. 
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Abbasi et al studied the importance of AgNOR in differentiating 
keratoacanthoma from squamous cell carcinoma.[14] 
 
AgNORs are also useful as a proliferative tumour marker in 
desmoid tumour.[15]  
 
AgNOR in cervical lesions: 
Kaushik et al conducted a study to assess the utility of  AgNOR 
counts in differentiating cervical lesions.Mean AgNOR  counts showed a 
statistically significant increase from normal to chronic cervicitis to CIN 
1,2&3.This study proved that AgNOR count is an useful adjunct to 
routine histopathology to evaluate cervical lesions[16]. 
 
                 Srivatsava et al investigated regarding the usefulness of 
AgNOR pleomorphism to assess the progression of cancer cervix. They 
have found that the pleomorphism of AgNOR increases with progression 
of cervical lesions and highest number is seen in squamous cell 
carcinoma[17]. 
 
Alarcon Romero et al [18] reported that significant difference was 
found with various types of AgNOR dots with infection of high risk HPV 
types. They concluded that study of HPV types and polymorphism of 
AgNOR can be useful as prognostic factors to estimate the progression of 
cervical lesions. 
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Terlikowski et al conducted a study to correlate between the 
number of AgNOR granules and degree of CIN. Number of cells with 1 
dot decrease with increasing grade and number of cells with 4 or more 
increased with increasing grade of cervical lesions.[19] 
 
 Misra Js et al studied 50 cervical smears and found an increase in 
AgNOR count with progression of cervical lesions.[20] 
 
 AgNORs in cervical cytology is an adjunctive tool to PAP stained 
smear and help in finalising the diagnosis.Shukla et al emphasis the fact 
that the AgNORs can be declared as a definitive index for assessing the 
cell proliferative activity.[21] 
 
                   Ritu et al employed AgNOR staining in 112 female patients 
and observed that there is a significant increase of AgNOR count in 
malignant lesions than in premalignant and benign conditions.[22] 
 
Vijaya et al compared the various proliferative and apoptotic 
indices in different cervical lesions and concluded that AgNOR counts 
are useful cell kinetic analyzer and aid in patient management decisions. 
In this study maximum counts were obtained in invasive carcinoma[23] 
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PREINVASIVE AND INVASIVE LESIONS OF CERVIX 
 
Cancer cervix has been the most important cancer in 
India.Mortality from cervical cancer is expected to increase to 79% from 
74,118 to 1,32,745 deaths by 2025.(NATIONAL CANCER REGISTRY 
PROGRAMME 2009). 
 
Incidence of cervical dysplasia is 15:1000 in women who were 
cytologically screened and severe dysplasia is reported to be 5:1000. In 
Tamilnadu ,Chennai had the highest incidence rate of cervical cancer 
among population based cancer registries. 
 
Cervical cancer is curable and preventable by detecting it in an 
early stage(WHO,2006).5yr survival rate for the women when detected at 
earliest stage is 92% and for all stages is 71%(American cancer society 
2009).women can develop CIN at any age, however women generally 
develop it between the ages of 25-35yrs.2,50,000-1 million women were 
diagnosed with cervical dysplasia in developed countries(Stanley et al 
JAN 2013). 
 
As cervix can be easily accessible, cancer cervix can be diagnosed 
even in its preinvasive stage. If it is treated in early stages, the patient can 
be cured of the disease. 
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ANATOMY OF CERVIX: 
 Cervix is spindle shaped and measures about 2.5cm.mucosal lining 
of cervix differs from the body of uterus by the absence of 
submucosa.cervix contains more of fibrous tissue and collagen than 
muscle fibers. 
 
ENDOCERVIX: 
It extends from internal os to ectocervix. It contains the 
endocervical canal and lined by columnar epithelium which is thrown 
into folds and project into the underlying stroma forming cypts. 
 
FUNCTIONS: 
1. Cilia are directed downwards and it prevents ascending infection 
2. Cells sieve out abnormal sperms and it provides nutrition for 
healthy sperms. 
3. It allows capacitation of sperms. 
 
ECTOCERVIX: 
It extends from SCJ to vaginal fornices. It is hormone sensitive and 
covered by non keratinising stratified squamous epithelium. 
 
 
 
 14 
 
SQUAMO COLUMNAR JUNCTION: 
It is the most important junction where the squamous epithelium 
merges with columnar epithelium of ectocervix. Around 1-10mm.Here 
the cells are sensitive to irritants, mutagens and HPV 16,18. 
 
            It is the dynamic point that changes throughout life as a result of 
metaplastic changes in the columnar epithelium of cervix. The reserve 
cells lying beneath the columnar epithelium at this junction sometimes 
transforms into mature squamous cells known as metaplasia. Metaplastic 
cells are normal cells without nuclear atypia and do not become 
malignant. Atypical metaplasia with abnormal nuclear changes are the 
precursors of dysplasia and malignancy. 
 
Transition in SCJ occurs in various phases of life: 
1. Prepubertal period:  
Columnar epithelium spreads over the external os 
2. Puberty: 
Metaplasia of columnar epithelium under the influence of estrogen 
brings the squamous epithelium close to external os. 
3. Premenopausal: 
It gets drawn into external os. 
4. Pregnancy: 
Pouts out of os. 
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TRANSFORMATION ZONE: 
Metaplasia advances from original SCJ inwards towards the 
external os and this process establishes an area called transformation 
zone.it is the zone between original SCJ to physiologically active SCJ. 
 
It is visible as a distinct white line after the application 3-5% acetic 
acid. Transformation zone is the site of origin for 90% of precancerous 
and cancerous lesions. 
 
Reproductive age group women shows more active metaplasia than 
menopausal women and hence they are at low risk. 
 
SCJ is well outside the external os during reproductive period and 
this area can be screened for malignancy. 
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AETIOLOGY AND RISK FACTORS 
 
1.BIOLOGICAL RISK FACTORS: 
1. Herpes simplex virus 2 
2. Chlamydia trachomatis 
3. HIV 
 
Herpes simplex virus 2: 
 Seroprevalence was higher in a study than in control subjects 
conducted by smith et al and association was consistent in squamous cell 
carcinoma and adenocarcinoma.[25] 
 
Chlamydia trachomatis: 
Chlamydia trachomatis serum antibodies increases the risk of 
cervical cancer by 1.8 fold in all countries. The study suggests the 
possibility of Chlamydia trachomatis increases invasive carcinoma after 
accounting for HPV infection.[26] 
 
HIV: 
Ahdieh et al [27] identified  a higher incidence of cervical 
abnormalities among HIV infected women(13.4%) when compared to 
HIV negative women (2.4%)HPV and HIV share behavioural traits that 
define the high risk group.progression of cervical lesions is related to 
severity of immunosupression as indicated by CD4 counts. 
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BEHAVIOURAL RISK FACTORS: 
1. Smoking: 
Nicotine and tobacco are the specific carcinogens detected in 
cervical mucus of smokers.it indicates tha there exists a synergistic 
relationship  between cigarette smoking and HPV for development of 
dysplasia and carcinoma.[28] 
 
2.Coitus before the age of 18yrs 
3.Multiple sexual partners 
4.Multiparity 
5.Poor personal hygiene 
6.Infrequent or absent cancer screening pap tests 
 
7. Dietary: 
At present, none of the cohort studies asses suspected nutritional or 
dietary factor controlling HPV infection. Further studies are needed with 
long follow up periods. 
 
MEDICAL RISK FACTORS: 
ORAL CONTRACEPTIVE PILLS: 
A recent meta analysis on the association between OCPs and 
cervical cancer establishes the fact that there exists a linear dose response 
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relationship between years of use and risk of cervical neoplasia.Duration 
of risk after  OCP cessation is yet to be determined.[29] 
 
2.IMMUNOSUPRESSION 
DEMOGRAPHIC RISK FACTORS: 
1. Ethnicity 
2. Low socioeconomic countries 
3. Age 
 
HUMAN PAPILOMA VIRUS AND CERVIVAL CANCER: 
HPV genomes are found in all stages of cervical cancer.[30] HPV 
infection  is the initiating agent and is the primary cause of cervical 
cancer. [31] portions of HPV DNA integrates into host cell. This 
integration appears to be essential for malignant transformation which 
requires expression of E6 & E7 oncoproteins [32] 
 
Most women with cervical neoplasia expresses HPV DNA. More 
than 120 types of HPV DNA have been identified. Of these 120,30 types 
infects squamous epithelium of lower anogenital tract of men and 
women. 
 
90% of CIN is attributed to HPV infection. Type 16 is most 
commonly found in invasive cancer,CIN2 and CIN3.[33] 47% of women 
with cancer cervix in all stages infected with HPV 16.[34] 23% of women 
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with invasive cancers.5% of women with CIN2 &CIN3,<2% with 
negative findings are affected with HPV 18 [35].Thus HPV18 is more 
specific than HPV 16. 
 
Most of the time HPV infection does not persist. Those that 
persists may remain latent for many years. Most of the women have no 
clinical evidence of disease and the infection is suppressed or eliminated 
[36]. Others exhibit low grade cervical lesions that regresses 
spontaneously. Most probably the infection will clear in 9-15 
months.[37].Average time between HPV infection and pre cancer is about 
7-10 years. Only the minor population develops persistent infection that 
may progress to CIN. Persistent HPV infection increases the risk of high 
grade lesions and is required for the development and maintenance of 
CIN. 
 
HPV VACCINE: 
           Development of HPV vaccine is an important step in primary 
prevention. 
 
          GARDASIL is a quadrivalent vaccine containing virus like 
particles for HPV 6,11,16,18 approved in 2006. CERVARIX is a bivalent 
vaccine containing HPV 16 & 18.For the women who are seronegative 
and HPV DNA negative for HPV 16 & 18 at vaccination and received all 
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the three doses, vaccine is 100% effective. This protection lasts for 6.4 
yrs after vaccination.[38]Women who are seropositive,but DNA negative 
efficacy is 100%[39]Women who are HPV 16 & 18 DNA positive, 
vaccine donot show efficacy. These vaccines are not able to clear an 
active infection and are used to prevent CIN, not used to treat it.     
 
           HPV vaccine cross protects from other high risk types. Bivalent 
vaccine protects from persistent infection with HPV types 31,33 & 45 [40]. 
Quadrivalent vaccine shows cross protection against CIN2 and HPV 31 
[41]. Follow up for three years indicates that both vaccine reduces the 
referrals to colposcopy by 26% and 20% respectively [42]. It reduces the 
excisional procedures by 69% and 42% respectively. 
 
Quadrivalent vaccine prevents genital warts caused by HPV 6 & 
11.This vaccine gives 89% protection in men and boys against HPV 
infection. Hence this vaccine is approved for males. 
 
Women who were HPV negative at vaccination had 100% 
reduction in vaginal and vulvar intraepithelial neoplasia. The vaccinated 
women shows only50% reduction in VIN AND VAIN. This data reveals 
that HPV types other than 16 & 18 are responsible for a significant 
proportion of VIN & VAIN. So women who are already positive for HPV 
16 & 18 are not protected from VIN &VAIN. 
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To improve the significant antibody response to the antigen,it is 
combined with adjuvant.In quadrivalent vaccine,the adjuvant is 
aluminium hydroxyphosphate sulphate.In bivalent vaccine,the adjuvant is 
aluminium hydroxide combined with monophosphoryl lipid A.This 
provides a link between HPV and activation of innate immune system 
and it provides higher antibody titers than aluminium adjuvant [45]. 
 
Whether booster dose is needed after vaccination is not yet 
approved as most of the women at their twenties get exposed to HPV at 
the maximum. As first vaccination is given less than 10 years, it is 
advisable to give booster, but not yet proved as the studies are ongoing. 
 
In 2007, American cancer society issued a guidelines. According to 
age, HPV vaccine may be provided as early as 9 years and as late as 18 
years. For young women between 19-26, there are insufficient data 
.Screening practices for cervical cancer and dysplasia should remain 
unchanged for both vaccinated and unvaccinated women. 
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PREMALIGNANT AND MALIGNANT LESIONS OF CERVIX 
 
                CIN –It is the histopathological terminology in which part or 
full thickness of stratified squamous epithelium is replaced by cells 
showing varying degrees of dysplasia. Basement membrane however is 
intact. 
 
               Dysplasia refers to alteration in cell size,shape and polarity.The 
term dysplasia was first introduced by Reagen in 1953. 
 
            There is an alteration in nucleolar cytoplasmic ratio and 
hyperchromatic nuclei with marginal condensation of chromatin and 
mitotic  f igures.This progresses and ends up in invasive cancers. 
 
According to woodruff and novak(1979),three degrees of dysplasia: 
MILD: 
 Dysplastic cells are confined to lower one third of epithelium. 
 It may be due to infection in young women indulging in sexual 
activity. 
MODERATE: 
 Dysplatic cells confined to lower 50-75% of epithelium. 
 Mostly the cells are intermediate type 
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SEVERE: 
 Entire thickness of epithelium replaced by dysplatic cells. 
 Cornification and stratification is lost. 
 Basement membrane intact. 
 No stromal infiltration. 
 Cells are mostly parabasal. 
 
ICMR reports an incidence of dysplasia to be 15:1000 women who 
are cytologically screened [shaw]. Richart in 1966 first introduced the 
term CIN to denote intraepithelial abnormalities of varying degrees. 
 
FEATURE VARIATIONS WITH INCREASING SEVERITY OF 
DYSPLASIA : 
DECREASE INCREASE VARIES 
Amount of cytoplasm 
Cellular cohesion 
Multinucleation 
Degree of maturation 
Normal flora 
N/C ratio 
Mitosis 
Anisochromatism 
Nuclear membrane 
irregularities 
Hyperchromatic nuclei 
Anisokaryosis 
Nuclear hypertrophy 
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PROGRESSION AND REGRESSION OF CIN: 
Cin Regress Persist 
Progress to 
CIN3 
Progress to 
Carcinoma 
CIN 1 57% 32% 11% 1% 
CIN2 43% 35% 22% 5% 
CIN3 32% 56% - >12% 
 
(FROM OSTOR AG – INTERNATIONAL GYNAECOLOGY 
PATHOLOGY 1993;12) 
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SCREENING PROCEDURES 
1. PAP TEST: 
     Screening for cervical cancer precursors using exfoliative cervico 
vaginal cytology, the pap test was successful in reducing the incidence of 
cervical cancer by 79% and mortality by 70% since 1950[46] 
 
             Cytology based screening program can be implemented 
effectively only if infrastructure and lab quality assurance are consistently 
met. Various studies have demonstrated limited sensitivity of 
conventional pap cytology ranging between 30-87%This is an area of 
major concern as high false negative rates results in premalignant and 
malignant cells being misdiagnosed as normal. Consequently, the test 
needs to be repeated at frequent  to achieve programme effectiveness.pap 
test has repeatedly demonstrated good specificity ranging from 86-100%. 
 
       Pap smear should be obtained prior to vaginal examination by 
placing the patient in dorsal position using cuscos speculum after 
visualising SCJ. Cervix is exposed and SCJ is scraped by Ayre’s spatula 
around 360 degree. 
 
          Scrapings spreaded to glass slide and fixed by using 95% ethyl 
alcohol and ether. Fix for 30 minutes, air dried and then stained. 
conventional pap test technique needs to be improved in order to reduce 
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false negative errors. Sampling errors occurs because a lesion is too small 
to exfoliate cells or the device did not pick up the cells and transfer them 
to the fixation media. To overcome this, several new technologies like 
LBC and automated pap smears are being explored. 
 
DRAW BACKS OF PAP SMEAR: 
SENSITIVITY  :  not very high 
YIELD OF CELLS :  20% 
ERRORS   :    in sampling 
 
Interpretation   detection 
Low false negative rate :  10%-29% 
High specificity  : 97-100% 
Low sensitivity  :  29-56% 
 
LIMITATIONS OF PAP SMEAR: 
1. Complex laboratory test. 
2. Requires cyto-technician for reading and pathologist for review. 
3. Continuous monitoring needed to maintain high quality results. 
4. Reports often take minimum of 1-2wks. 
5. Follow up of women is difficult. 
6. Usually available in large cities in many countries. 
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LIQUID BASED CYTOLOGY: 
Cells are collected using a very small brush that is broken off into a 
small pot containing preservative solution. In the cytology lab, sample is 
filtered or centrifuged to remove excess blood and debris and the cells are 
then transferred to the slide in a monolayer. It interprets at higher speed, 
lower rate of unsatisfactory smears and possibility of ancillary molecular 
testing using remnant fluid. More expensive and requires sophisticated 
equipment. 
 
Automated pap smears, the material on the slide is reviewed and 
scored based on algorithm. This includes variety of visual characteristics 
such as shape and optical density of cells as to the likelihood of an 
abnormality being present. Auto pap selects a sample of slides for manual 
re-screening that are enriched with abnormalities. Manual review is 
undertaken for cases which is designated by either the cytologist or the 
complete ranking as abnormal. 
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CLASSIFICATION OF PAP SMEAR : 
Pap Class 
System 
(1954) 
Scheme 1 Reagen 
(1956)(WHO) 
Scheme 11 
Ruchart 
(2001) 
Scheme 111 Bethesda 
(1988) 
CLASS1 
CLASS2 
CLASS3 
CLASS4 
CLASS 5 
Negative for 
malignant cells 
Koilocytes 
Mild dysplasia 
Moderate dysplasia 
Severe dysplasia 
Carcinoma in situ 
Invasive cancer 
Negative 
CIN-1 
CIN-2 
CIN-3 
INVASIVE 
CANCER 
Within normal limits 
Reactive and reparative 
changes(ASCUS) 
LSIL 
HSIL 
Invasive cancer 
 
HPV BASED SCREENING TEST: 
Possible clinical applications of detecting high risk HPV DNA are  
1. As a primary screening test, solely or in combination with cytology 
to detect cervical cancer precursors. 
2. As triage for women with cytology findings of ASCUS  or LSIL in 
order to select women who need referral for colposcopic diagnosis 
and treatment. 
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3. In subsequent management of women referred for colposcopy due 
to abnormal smears but where findings on colposcopy/biopsy are 
negative. 
4. As a follow up test for women treated for high grade CIN with 
local ablative or excisional therapy in order to identify and 
accurately evaluate the treatment outcomes. 
 
Hybrid capture technology is the most commonly used test.HPV 
DNA testing is more sensitive but less specific than cytology in detecting 
high grade lesions. Lower specificity is due to presence of infection 
without any cytological changes.  
 
HPV DNA test which is more sensitive should be applied first 
followed by cytology which is more specific to determine the 
management.HPV negativity or a combination of HPV and negative 
cytology denotes a longer disease free interval against CIN2. 
 
Follow up results of a RCT involving single round screening in low 
resource settings demonstrates reduction in numbers and deaths from 
cervical cancer with HPV testing. 
 
Investigators found that HPV testing to be most objective and 
reproducible of all cervical screening tests. It is less demanding in terms 
of quality assurance and training. With the availability of simple, 
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affordable and accurate HPV test, this can be used as a primary screening 
in low resource settings for women of atleast 30yrs of age.[47] 
 
Care HPV is a new test which is very simple and can be performed 
even by health care workers. Evaluation of clinical accuracy of care HPV 
showed it to be substantially better than visual inspection methods with 
sensitivity and specificity of 90%&84.2%respectively on specimens 
collected by nurse midwife.[48] 
 
VISUAL INSPECTION METHODS: 
In developing countries, it has been difficult to maintain effective 
cervical cytology programs due to lack of resources, trained man power, 
infrastructure and requirement of multiple visits. 
 
Low cost alternative method is visual inspection of cervix with 
VIA/VILI. Medical as well as paramedical staff can be easily trained. 
Application of 3-5% dilute acetic acid on the cervix during VIA results in 
reversible coagulation of cellular proteins. The areas with dysplasia or 
invasive cancer undergoes maximal coagulation due to large number of 
undifferentiated cells in the epithelium that have a reversal of N/C ratio. 
Therefore these areas appears acetowhite. 
 
During VILI, normal squamous epithelium containing glycogen 
takes up iodine staining mahogany brown or black. The precancerous 
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cells and invasive cancer do not take up iodine due to lack of glycogen 
and appear as well defined thick mustard or saffron yellow areas. 
 
Sensitivity and specificity in a pooled analysis of eleven cross 
sectional studies were 77% and 86% for VIA,91% and 85% for VILI 
respectively.[49] 
 
4.COLPOSCOPY: 
 Colposcope is a binocular microscope. Useful in locating abnormal 
areas and directing biopsy so the need for conisation is reduced. 
 To study the cervix when pap smear detects abnormal cells. 
 To locate the abnormal areas and take a biopsy. 
 To study the extent of abnormal lesion. 
 Conservative surgery under colposcopic guidance. 
 Follow up of conservative therapy cases. 
 Abnormal areas are acetowhite areas, punctuation, mosaic pattern 
and atypical vessel pattern. 
 Punctuation referred to as dilated capillaries terminating on the 
surface appear from the ends as a collection of dots. 
 Mosaics are the terminal capillaries surrounding roughly circular or 
polygonal shaped blocks of acetowhite epithelium. 
 Atypical vessel pattern seen in invasive cancer and it includes 
branching,reticular and looped vessels. 
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CERVICAL BIOPSY: 
It is the gold standard confirmatory test. Punch biopsy, conisation 
biopsy and loop excision biopsy are the different types of biopsy methods 
done. Punch biopsy is the most common method practiced but it does not 
include stroma. 
 
Cone biopsy is both diagnostic and therapeutic. It causes bleeding, 
infection, cervical stenosis and cervical incompetence. 
 
AgNOR COUNT: 
          It is a new molecular tumour marker which stands for silver stained 
nucleolar organizer regions. 
 
ADVANTAGES: 
1. Low cost 
2. It can be used in cytological smears and tumour material 
3. Does not require fixatives. 
 
DISADVANTAGES: 
1. Counting procedures are manual and hence long and tedious 
2. Sometimes inaccurate due to observer error 
3. Overlap and coalescence may result in misjudged counts as 
denoted by crocker et al. 
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SCREENING INTERVALS 
 
DEVELOPED COUNTRIES: 
ACOG GUIDELINES: 
 Initial screening :  At the age of 21 or 3yrs after vaginal sex. 
 Interval between screening: Every year for either liquid based pap 
or conventional smear. Every 2-3 year after age 30 with three 
consecutive normals. 
 More frequent screening for HIV positive women (twice for first 
year and annually after). 
 Discontinuation for screening is reasonable between 65 to 70 yrs, 
with reassessment of risk factors annually. 
 In the setting of posthysterectony for benign indications, it is 
reasonable to discontinue screening in the absence of history of 
high grade CIN or cancer. 
 
DEVELOPING COUNTRIES: 
In low resource settings, where screening programmes are 
organised less effectively, single or two screening in lifetime may be the 
only option. Greatest public impact is achieved by screening women 
between 30-39yrs of age. 
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Screening once at 35yrs with VIA or HPV DNA leads to reduction 
in lifetime risk of cervical cancer by 25-36%.screening twice (at 35 & 40 
yrs of age) provides life time reduction risk by 40% [50] 
 
Choosing a suitable screening test with good efficacy and one 
which is feasible, affordable for implementation with respect to available 
technical expertise and man power is an important aspect of a screening 
programme. 
 
It is important to identify the factors which determine the 
participation of women, incorporating a comprehensive health education 
programme prior to screening, personal invitations, proximity of clinics 
to the target women all help in increasing compliance. 
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                                  MANAGEMENT OF CIN 
 
TREATMENT MODALITIES: 
1. Ablation Techniques 
2. Excision Techniques 
 
ABLATION TECHNIQUES: 
1. Cryosurgery 
2. CO2 laser vapourization 
 
CRYOSURGERY: 
It destroys the epithelium of cervix by causing destruction of the 
cell by crystallizing intracellular water. Temperature required is -20 to -
30 degree celcius.NO2 and CO2 are the most commonly used gases for 
this purpose. 
 
Use of double freeze technique with 3min interval each of freeze 
thaw freeze improves the efficacy. Probe should cover the entire lesion 
and have to create a 4-5mm ice ball beyond the edge of the probe. The 
women should abstain from intercourse for 4weeks. 
 
ADVANTAGES: 
1. Outpatient procedure 
2. Low cost 
3. No bleeding 
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DISADVANTAGES: 
1. No tissue specimen for HPE  
2. Profuse white discharge 
3. Cephalad migration of  SCJ 
 
Townsend showed that cure rates are related to the size of the 
lesion. positive findings on ECC causes reduction in cure rate. 
Endocervical gland involvement also causes failure rate of 27% 
compared to 9% those who did not have much involvement. [51] 
 
CRITERIA FOR CRYOTHERAPY: 
1. The entire lesion is located in the ectocervix without extension to 
the vagina.   
2. The lesion is visible in its entire extent and does not extend more 
than 2-3mm into the canal. 
3. CIN is confirmed by cervical biopsy/colposcopy. 
4. There is no evidence of invasive cancer 
5. The women is not pregnant. 
6. There is no evidence of pelvic inflammatory disease. 
7. The women has given informed written consent to have the 
treatment. 
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LASER ABLATION: 
               This procedure gained popularity in the mid 1980s.It is also 
performed as a OP procedure. But nowadays it is rarely used in practice. 
It vapourizes tissue to a depth of 5-7mm.Well suited for large, irregular 
lesions of all grades. 
 
ADVANTAGES: 
1. Healing after laser surgery is rapid 
2. Minimal side effects including minimal vaginal discharge 
3. Less cervical narrowing and a lower stenosis rate 
4. No diminution of fertility 
5. No obstetric complications 
6. Laser does not cause in drawl of SCJ and therefore repeat laser is 
possible for residual lesion unlike cautery or cryosurgery 
 
DISADVANTAGES: 
1. Its acquisition expense. 
2. Time required to acquire and maintain laser skills. 
3. High maintenance cost of the instrument. 
 
Use of the C02 laser for the management of CIN has decreased 
dramatically since introduction of LEEP. 
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LLETZ AND LEEP: 
Electro-cautery was used extensively as a destructive procedure. 
Large Loop Excision Of Transformation Zone and Loop Electrosurgical 
excision procedure have been used to describe a technique to excise the 
transformation zone with electro-cautery current. It was described in 
Europe initially and extensively used in great Britain. 
 
        Under paracervical block or local infiltration of cervix with 
colposcopic guidance, area to be removed is visualised. An appropriate 
loop size is selected to a depth of 6 - 7mm, extending 4-5mm beyond the 
affected area.60-80 watt will allow smooth excision and decrease the 
tissue resistance. After excision of an abnormal cervical tissue, bleeding 
areas are cauterized with ball electrode using coagulation current and 
monsel solution. 
 
LEEP: 
 It is even simpler than LLETZ .LEEP is applicable anywhere in the 
lower genital tract whereas LLETZ is applicable only to the cervix. 
 
ADVANTAGES: 
1. Outpatient procedure 
2. It is under colposcopic control and has the advantage of being 
diagnostic and therapeutic procedure at the same time. 
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3. Easy to learn, to teach and to apply. 
4. Provides tissue specimen for HPE. 
 
DISADVANTAGES: 
1. Produces thermal damage. 
2. Sometimes causes significant bleeding. 
3. Cervical stenosis. 
4. Increased risk of preterm labour, preterm premature rupture of 
membranes, low birth weight in ubsequent pregnancies. 
5. Cervical stenosis. 
 
CO2 LASER CONIZATION: 
This technique is burdened by need for regional/general 
anaesthesia. Laser cone surgical specimens may have significant cautery 
artefacts which make histopathological evaluation cumbersome. 
 
LEEP technique is more efficient, easily mastered and has 
widespread applicability. It has replaced laser cone. 
 
LEEP technique produces minimal cautery artefact with 
appropriate power settings.[52] 
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CONIZATION: 
 This technique plays an important role in the management of CIN. 
Traditional cold knife conisation has been used successfully for 
generations to excise lesions that extends into the endocervical canal or to 
rule out invasive cancer. Before the advent of colposcopy, it was used to 
evaluate an abnormal pap results. It is both diagnostic and therapeutic 
procedure. 
 
INDICATIONS: 
1. Colposcopy fails to demonstrate the limits of the lesion 
2. SCJ not seen at colposcopy 
3. ECC positive for CIN2 OR CIN3 
4. Lack of correlation exists between cytology.biopsy and colposcopy 
results. 
5. Suspected microinvasive lesions based on biopsy,colposcopy or 
cytology results 
6. Colposcopist unable to rule out cervical cancer. 
 
 Lesions with positive margins recurs after conisation [53,54,55]. 
Endocervical gland involvement also results in recurrence.[56] LEEP is 
simpler technique when compared with conization. 
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LEEP, conization and laser excision showed no difference in 
recurrence of dysplasia or in pregnancy outcomes by examining the long 
term effects of all these procedures in a prospective study [57]. 
 
COMPLICATIONS: 
1. Significant bleeding may occur in the first 24 hrs or 10-21 days 
after surgery when sutures dissolve. 
2. Cervical stenosis occurs in about 3% of patients 
3. Size of the cone is related to the risk of premature labour. The 
larger the cone, the greater is the risk. 
 
HYSTERECTOMY: 
It is the last resort for recurrent high grade CIN. In the study of 
38cases of invasive cancer, the incidence of significant bleeding, 
infection and other complications including death is higher in this 
procedure. 
 
INDICATIONS: 
1. Microinvasion 
2. CIN3 at the endocervical limits of conization specimen in selected 
patients. 
3. Poor compliance with follow up 
4. Other gynaec disorders requiring hysterectomy 
5. Histologically confirmed recurrent grades of CIN. 
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Many different treatment techniques are available for cervical 
dysplasia. In general, ablative or destructive techniques such as 
cryotherapy or laser ablation are less injurious to the cervix and have a 
lower risk of cervical incompetence in future pregnancies. 
 
Excisional techniques such as LEEP provide a specimen for 
histologic confirmation of the diagnosis. The severity and the size of the 
lesion together with the desire for future pregnancy and the training of the 
surgeon and availability of the equipment all help to guide the choice of 
treatment technique. 
 
COMPARISON OF ABLATIVE TECHNIQUES: 
 Cryotherapy Laser ablation 
Cost and portability Cheap Expensive 
Depth of destruction 4-5mm 7mm 
Sepsis Discharge Nil 
Healing 6-8wks 4wks 
Post op tz Indrawn Seen 
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COMPARISON OF EXCISIONAL TECHNIQUES: 
Characteristics 
Laser 
conization 
Cold knife 
conization 
LLETZ LEEP 
Admission OPD needed OPD OPD 
colposcope used Not used used used 
anaesthesia local GA local local 
bleeding slight ++ slight - 
sepsis nil + slight slight 
Scarring and 
stenosis 
7% 26-36% rare rare 
 
WHAT CAN BE DONE TO PREVENT CERVICAL CANCER: 
1. PRIMORDIAL PREVENTION :  Change of behaviour 
2. PRIMARY PREVENTION  :  HPV vaccine 
3. SECONDARY PREVENTION :  screening 
 
60% of cervical cancer cases will occur in women who have never 
had a screening test. Will enable to control carcinoma cervix by 
diagnosing it early in a stage when treatment can give 100% cure rate. 
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Cervical cancer is particularly well suited for screening because 
1. Cause is understood (HPV, especially 16 & 18- 70 - 75% of cancer 
cervix). 
2. Early stage precursors of the disease can be identified(long pre 
invasive state) 
3. Simple outpatient procedure that can treat precursor lesions with a 
high degree of success. 
 
COMPARISON BETWEEN VIA AND CYTOLOGY: 
 Sensitivity(%) Specificity(%) 
CYTOLOGY 29-56 97-100 
VIA 76-84 79-83 
 
SCREENING METHODS  PERFORMANCE: 
Screening Tests Sensitivity  
 Specificity 
Conventional cytology 44-78% 91-96% 
HPV-DNA TESTING 66-100% 61-96% 
VIA 67-79% 49-86% 
VILI 78-98% 73-93% 
COLPOSCOPY 67-74% 65-72% 
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OMANABAD RCT OF CERVICAL SCREENING INDIA 
RESULTS OF TREATMENT OF CIN 
Treatment Total number Cured (%) 
CRYOTHERAPY 562 477(85%) 
LEEP 422 357(85%) 
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MATERIALS AND METHODS 
 
This study was conducted in our department of obstetrics and 
gynaecology, Tirunelveli medical college in the period of may 2013 to 
may 2014. 100 patients from gynaec ward and gnaec OPD were selected 
after obtaining informed written consent. 
 
INCLUSION CRITERIA: 
1. AGE 20-70 yrs 
2. Patients with symptoms like profuse white discharge, post coital 
bleeding, intermenstrual and post menopausal bleeding. 
3. Patients with erosion, growth and ulcer diagnosed by speculum 
examination. 
4. Patients with pap smear showing dysplasia 
 
EXCLUSION CRITERIA: 
1. Women with age >70 and <20 yrs 
2. Pregnant women 
3. Women who does not have undergone sexual intercourse 
4. Women who underwent hysterectomy or other ablative procedures. 
 
100 patients from gynaec OPD and ward were randomly selected. 
A detailed history regarding Age, socioeconomic status, educational 
status, parity, age at marriage, contraceptive usage and obstetric history 
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were recorded, which was followed by thorough gynaecological 
examination, cervix biopsy taken from all patients. 
 
TECHNIQUE OF PUNCH BIOPSY OF CERVIX: 
                 After placing patient in lithotomy position, labia were 
separated and cervix visualised by introducing the sim’s speculum into 
the vagina. Biopsy was taken using punch biopsy forceps, specimen was 
put in 10%formalin and sent for HPE. 
 
             After paraffin embedding, thin sections were made and stained. 
Apart from the routine H&E stain, AgNOR staining were used. 
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AgNOR STAINING 
 
MATERIALS FOR STAINING: 
1. 5micron thin histopathological sections 
2. 50%aquous silver nitrate solution 
3. 2%gelatin 
4. 1%formic acid 
 
METHODS FOR PREPARING AgNOR STAINING: 
Silver stain was used to identify NORs,to evaluate their function 
and to identify the chromosomes in cytogenetic preparations. 
 
This was first applied by ploton et al (1986), subsequently 
popularized by crocker et al. 
 
1. Sections were deparaffinised in xylene 
2. Hydrated through 100% and 95% ethanol to water 
3. Silver stain was prepared by mixing 2%gelatin in 1%formic acid at 
room temperature 
4. Solution was filtered through filter paper 
5. One part of solution was mixed with 2 parts of 50%silver nitrate 
immediately before use. 
6. Staining done at dark room temperature for 30-35 min 
 52 
 
7. Sections were washed thoroughly in water,dehydrated using 95% 
and 100%ethanol 
8. Sections mounted in a permanent mounting medium. 
 
AgNOR SCORE: 
        Stained slides were viewed under oil immersion and silver dots are 
manually counted using light microscope. AgNORs were identified as 
dark brown/black intranuclear dots. Number of dots were identified in 
each nucleus. 
 
        Clusters of several AgNOR were interpreted as a single unit if the 
dots are not identified separately.AgNOR score was expressed as mean 
AgNOR after counting atleast 100 cells. 
 
Two methods to calculate AgNOR score: 
1. Counting method 
2. Morphometric method 
 
             We followed counting method i.e, manual method by carefully 
focusing through the section thickness at very high magnification. to 
prevent the counting errors,it was repeated by another person. 
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RESULTS AND ANALYSIS  
 
Statistical analysis and interpretation: 
 The study subjects were described in respect of their demographic 
characteristics in terms of mean and proportions, which ever applicable. 
Similarly the socio economic and clinical characteristics of them were 
described in terms of proportions. The above profiles with Histo 
Pathological Examination were associated by χ2 (Chi-square) test. The 
relationship between continues variable more than two groups and 
AgNOR score were studied by ANOVA and Pearsonic correlation 
coefficients. The dichotomous attributes and AgNOR score relationships 
were studied by Students  ‘t’ test. The HPE cervical lesions and AgNOR 
score were studied by ANOVA. The above statistical procedures were 
performed by the statistical package namely IBM SPSS statistics-20.The 
P≤0.05 was considered as statistically significant in two tail test.  
 
Results: 
Description of Study Subjects:  
 The study subjects were described in terms of their demographic, 
socio economic and clinical features namely age, education, economic 
status, parity, duration of married life, multiple partner, contraceptive 
practice, previous screening, STD History, bleeding and white discharge, 
SE erosion and growth. 
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Table: 1. Age distribution of cervical lesions women 
Age group (years) No of women Percentage 
20-29 5 5.0 
30-39 29 29.0 
40-49 27 27.0 
50-59 28 28.0 
60-69 11 11.0 
Total 100 100.0 
Mean ± Std deviation 44.8±10.2 years. And range 24-60 years. 
The table 1 describes the age distribution of the women with 
cervical lesions. Among them the maximum (29%) of women in the age 
bracket of 30-39 and the least (5%) in the age group of 20-29 years. The 
other age groups of 40-49 and 50-59 were 27% and 28% respectively. 
The mean age of them was 44.8±10.2 years.  
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Table: 2. Educational status of study subjects. 
Educational Status No of women Percentage 
illiterate 55 55.0 
< 10th Std. 27 27.0 
10th and above. 18 18.0 
Total 100 100.0 
The above table-2 shows the educational status of the study 
subjects. Majority (55%) of women were illiterates. One fourth (27%) of 
the women had studied 10th or up to 10th std. The remaining 18% had 
studied 10th and above std. 
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Table:-3.  Classification of women according to income status: 
Monthly Income 
Status 
No of women Percentage 
<1000 65 65.0 
1000-1500 23 23.0 
1500-2000 12 12.0 
Total 100 100.0 
The table 3 states the monthly income of the women. Among them 
65% of women had their monthly income Rs. <1000. The remaining 23% 
and 12% of women had their monthly income in between 1000-1500 and 
1500-2000 respectively.   
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Table: 4 Parity distribution of cervical lesions women  
Parity No of women Percentage 
0 1 1.0 
2 34 34.0 
3 37 37.0 
4 22 22.0 
5 6 6.0 
Total 100 100.0 
Mean ± Std deviation 3.0±0.9 
The table 4 describes the parity level of the mothers. Among them 
1% of mothers  had no parity. Majority (37%) of mothers had the parity3. 
The second, fourth and fifth para mothers were 34%, 22% and 6% 
respectively. The mean parity of the mothers was 3.0±0.9. 
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Table: 5 Duration of married life of the study subjects:  
Duration of Married life 
years 
No of women Percentage 
<10 14 14.0 
10-20 24 24.0 
20-30 26 26.0 
30-40 26 26.0 
40-50 10 10.0 
Total 100 100.0 
Mean ± Std deviation 
The table 5 states the duration of married life of the women. Out of 
the above only 10 and 14 percentages of women had their married life 
<10 years and 40-50 years respectively. The maximum (26%) of women 
had their married life in 20-30 and 30-40 years each. The remaining 24% 
had their married life between 10-20 years.  
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Table: 6. Distribution of Multiple partners of the subjects. 
Multiple Partners No of Women Percentage. 
Nil 99 99.0 
Yes 01 01.0 
Total 100 100.0 
Table 6 states the multiple partners of the study women. Majority 
(99%) of women did not have multiple partners and only 1% of women 
had multiple partners.  
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Table:-7. Practice of contraception: 
Contraception No of women Percentage 
Barrier 3 3.0 
IUD 11 11.0 
Oral Pills 2 2.0 
Permanent 55 55.0 
NIL 29 29.0 
Total 100 100.0 
The Table-7 states the contraceptive practice of study women. 
Among them the maximum (55%) number of women were practicing 
permanent methods namely tubectomy. Next to that 29% of women were 
not practicing any one of the methods. The IUD, Barrier and Oral pills 
were practiced by 11, 3 and 2 percentages respectively.  
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Table: 8. History of previous screening. 
Screening history No of women Percentage 
Nil 93 93.0 
Yes 7 7.0 
Total 100 100.0 
The previous history of screening was found in the above table-8. 
Among the subjects 93% did not have any history of screening and only 
7% had the same. 
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Table:9. Findings of Speculam examination (SE). 
SE Findings Results No of women Percentage 
Erosion 
No 54 54.0 
Yes 46 46.0 
Total 100 100.0 
Growth 
No 69 69.0 
Yes 31 31.0 
Total 100 100.0 
Table-9 reveals that 54% of had no erosion and 46% had it. But the 
growth was not found in 69% and found in 31% of the study women. 
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Table:10. Distribution of bleeding, white discharge and both. 
Category Results No of women n=100 Percentage 
Bleeding 
Nil 51 51.0 
IMB 8 8.0 
PMB 34 34.0 
PC 7 7.0 
White discharge 
No 40 40.0 
Yes 60 60.0 
Both YES 14 14.0 
The above table 10 states the bleeding and white discharge of the 
mothers. In respect of bleeding more than half (51%) of the mothers no 
bleeding and the IMB,PMB and PC had 8%, 34% and 7% respectively. 
Majority (60%) had bleeding. Only 14% had both. 
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Table: 11 Histopathological examinations of study subjects: 
Histopathological examination No of women Percentage 
Chronic cervicitis 45 45.0 
Metaplasia 2 2.0 
Mild dysplasia 8 8.0 
Severe dysplasia 12 12.0 
Well differentiated squamous cell 
carcinoma  
11 11.0 
Moderately differentiated squamous cell 
carcinoma 
19 19.0 
Adeno carcinoma 3 3.0 
Total 100 100.0 
The table 11 classifies the study subjects according to their 
carcinoma characteristics. Nearly half (45%) of them were having 
Chronic cervicitis and 2% reported with Metaplasia. Mild and Severe 
dysplasia cases were 8 and 12 percentages respectively. Well and 
Moderately differentiated squamous cell carcinoma cases were 11 and 19 
percentages respectively. 
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Association between characteristics and HPE findings: 
Table:12. Age and HPE findings 
Age 
group 
Histopathological findings 
Total 
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20-29 5 0 0 0 0 0 0 5 
30-39 17 2 5 1 3 1 0 29 
40-49 14 0 3 0 6 2 2 27 
50-59 8 0 0 13 2 4 1 28 
60-69 1 0 0 5 1 4 0 11 
Total 45 2 8 19 12 11 3 100 
χ2 62.271 df=24, P<0.001 
The table 12 associates age and histopathological findings of study 
subjects. The age and HPE findings strongly associated (P<0.001). That 
means that incidence of cervical cancer increases according to increase in 
age of women. 
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Table:13. Educational status and HPE findings: 
Edun. 
Status 
Histopathological findings 
Total 
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Illiterat
e 
19 1 4 16 5 8 2 5 
<10 Std 16 1 3 1 2 3 1 29 
10th& + 10 0 1 2 5 0 0 27 
Total 45 2 8 19 12 11 3 100 
χ2 18.98 df=12, P=0.089 
The table 13 states the association between educational status and 
carcinoma episodes. The results revealed that there was no significant 
association between the education and cervic cancer episodes of the 
women (P>0.05). 
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Table:14. Socio economic status and HPE findings 
SE status 
Histopathological findings 
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<1000 25 1 5 15 3 10 3 5 
1000-1500 14 1 2 2 4 1 0 29 
1500-2000 6 0 1 1 5 0 0 27 
Total 45 2 8 19 12 11 3 100 
χ2 22.241,df=12, P<0.001 
  
The table 14 shows the association between socio economic status 
of women and Cervical Ca. episodes. The two attributes were 
significantly associated (p<0.05). That means the prevalence among the 
low economic status women was more than high economic status women. 
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Table:15. Parity and HPE findings 
Parity 
Histopathological findings 
Total 
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0 0 0 0 0 0 0 1 5 
2 20 2 5 1 6 0 0 29 
3 18 0 2 6 4 5 2 27 
4 7 0 1 8 2 4 0 28 
5 0 0 0 4 0 2 0 11 
Total 45 2 8 19 12 11 3 100 
χ2 62.271 df=24, P<0.001 
The table 15 states the association between parity and HPE. The 
parity was strongly associated with Cervical Cancer (P<0.001). The 
incidence were increasing according to the increase of parity. 
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Table:16. Duration of married life and HPE findings 
Married 
life 
duration 
Histopathological findings 
Total 
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0-10 11 0 2 0 1 0 0 5 
10-20 15 1 3 1 2 1 1 29 
20-30 11 1 3 2 4 4 1 27 
30-40 8 0 0 12 4 1 1 28 
40-50 0 0 0 4 1 5 0 11 
Total 45 2 8 19 12 11 3 100 
χ2 57.121, df=24, P<0.001 
  
The table 16 states the association between duration of married life 
and HPE. The duration of married life was strongly associated with 
Cervical Ca. episodes (P<0.001). The incidence were increasing 
according to the increase of duration of married life. 
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Table:17. Contraceptive adoption and HPE findings 
C
on
tr
a
ce
p
ti
o
n
 Histopathological findings 
T
o
ta
l 
C
h
r.
 
C
er
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is
 
M
et
a
p
la
si
a 
M
il
d
 
D
ys
p
la
si
a Mod 
differ 
SCC S
ev
er
e 
D
ys
p
la
si
a Well 
differ 
SCC A
d
en
o
 C
A
 
Nil 11 1 1 8 4 3 1 29 
Barrier 3 0 0 0 0 0 0 3 
IUD 7 0 3 0 0 1 0 11 
Oral Pills 0 0 1 1 0 0 0 2 
Perm 24 1 3 10 8 7 2 55 
Total 45 2 8 19 12 11 3 100 
χ2 24.129, df=24, P=0.454 
The table 17 states the association between contraception and 
carcinoma episodes. The results revealed that there was no significant 
association between the contraception practice and cervical cancer 
episodes of the women (P>0.05). 
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Table:18. Multiple partners and HPE findings 
Multiple 
Partner 
Histopathological findings 
Total 
C
h
r.
 
C
er
v
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it
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a 
M
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d
 
D
ys
p
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si
a
 Mod 
differ 
SCC S
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er
e 
D
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p
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si
a
 Well 
differ 
SCC A
d
en
o
 C
A
 
Nil 45 2 8 18 12 11 3 99 
Yes 0 0 0 1 0 0 0 1 
Total 45 2 8 19 12 11 3 100 
χ2 4.305 df=6, P=0.635 
  
The table 18 shows the association between multiple partner and 
carcinoma episodes. The results revealed that there was no significant 
association between the multiple partner and cervical cancer episodes of 
the women (P>0.05).out of modesty, only one has accepted multiple 
partners. 
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Table:19. Bleeding and HPE findings 
Bleeding 
Histopathological findings 
Total 
C
h
r.
 
C
er
v
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M
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a
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a 
M
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d
 
D
ys
p
la
si
a Mod 
differ 
SCC S
ev
er
e 
D
ys
p
la
si
a Well 
differ 
SCC A
d
en
o
 C
A
 
Yes 12 0 2 18 4 11 2 49 
Nil 33 2 6 1 8 0 1 51 
Total 45 2 8 19 12 11 3 100 
χ2 41.654 df=6, P<0.001 
The table 19 states the association between bleeding and HPE. The 
bleeding was strongly associated with Cervical Ca. episodes (P<0.001).In 
all the patients with complaints of bleeding,majority of the patients 
presented with moderately differentiated carcinoma.(36.7%) 
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Table:20. White discharge and HPE findings 
White 
discharge 
Histopathological findings 
Tota
l 
C
h
r.
 
C
er
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M
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p
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a 
M
il
d
 
D
ys
p
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si
a Mod 
differ 
SCC S
ev
er
e 
D
ys
p
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si
a Well 
differ 
SCC A
d
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o
 C
A
 
Yes 36 2 5 6 9 1 1 60 
Nil 9 0 3 13 3 10 2 40 
Total 45 2 8 19 12 11 3 100 
χ2 29.142 df=6, P<0.001 
  
The table 20 states the association between white discharge and 
HPE. The white discharge was strongly associated with Cervical Ca. 
episodes (P<0.001). In all the patients with complaints of white 
discharge,majority of the patient presented with chronic cervicitis(60%) 
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Table:21. Both (white discharge and bleeding) and HPE findings 
Both 
Histopathological findings 
Total 
C
h
r.
 
C
er
v
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d
 
D
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p
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a
 Mod 
differ 
SCC S
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e 
D
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p
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a
 Well 
differ 
SCC A
d
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o
 C
A
 
Yes 5 0 1 5 1 1 0 13 
Nil 40 2 7 14 11 10 3 87 
Total 45 2 8 19 12 11 3 100 
χ2 4.249 df=6, P=0.643 
  
The table 21 shows the association between both and carcinoma 
episodes. The results revealed that there was no significant association 
between the both events and cervical cancer episodes of the women 
(P>0.05). 
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Table:22. Previous screening and HPE findings 
Previous 
screening 
Histopathological findings 
Total 
C
h
r.
 
C
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 Mod 
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a
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differ 
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d
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o
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Yes 3 0 0 1 1 2 0 7 
Nil 42 2 8 18 11 9 3 93 
Total 45 2 8 19 12 11 3 100 
χ2 3.220 df=6, P=0.781 
  
The table 22 shows the association between pre screening and 
carcinoma episodes. The results revealed that there was no significant 
association between the pre screening and cervical cancer episodes of the 
women (P>0.05). 
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Table:23. S/E- Erosion  and HPE findings 
S/E 
Erosion 
Histopathological findings 
Total 
C
h
r.
 
C
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D
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a
 Mod 
differ 
SCC S
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e 
D
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p
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a
 Well 
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SCC A
d
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o
 C
A
 
Yes 30 1 5 1 10 0 0 47 
Nil 15 1 3 18 2 11 3 53 
Total 45 2 8 19 12 11 3 100 
χ2 39.827 df=6, P<0.001 
The table 23 states the association between SE Erosion and HPE. 
The S/E- Erosion was strongly associated with Cervical Ca. episodes 
(P<0.001).  
66.6% of patients with chronic cervicitis,62% of patients with mild 
dysplasia and 84% of patients with severe dysplasia showed erosion 
cervix in their per speculum examination. 
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Table:24. S/E- Growth  and HPE findings 
S/E 
Growth 
Histopathological findings 
Total 
C
h
r.
 
C
er
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d
 
D
ys
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si
a Mod 
differ 
SCC S
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e 
D
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p
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a Well 
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SCC A
d
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o
 C
A
 
Yes 1 0 0 18 0 11 2 47 
Nil 44 2 8 1 12 0 1 53 
Total 45 2 8 19 12 11 3 100 
χ2 39.827 df=6, P<0.001 
 
 The table 24 states the association between SE Growth and HPE. 
The S/E showing Growth was strongly associated with Cervical Ca. 
episodes (P<0.001). 85.7% of invasive cancer presented with friable 
growth. 
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Relationship between characteristics and AgNOR scores: 
Table:25. Relation between age and AgNOR. 
Sl. 
No 
Age 
group 
n 
AgNOR 95% 
CI of 
mean 
‘F’ P Significance between 
Mean SD 
1 20-29 5 2.8 0.7 1.8-3.7 
10
.2
87
 
P
<
0.
00
1 
The AgNOR Means of 
2&3, 4&5 were Not 
significant. (P>0.05) 
All AgNOR means 
between the age groups 
were statistically 
significant. (P<0.05) 
2 30-39 29 3.4 1.7 2.8-4.1 
3 40-49 27 4.0 1.6 3.4-4.7 
4 50-59 28 5.5 1.8 4.8-6.2 
5 60-29 11 6.1 1.2 5.3-6.9 
 Total 100 4.4 1.9 4.0-4.8 
r=0.550 & P<0.001 
  
The above table 25 states the relationship between age AgNOR 
score. The age was increasing; the AgNOR score was also increasing. 
Both were positively significantly correlated. (r=0.550 and P<0.001).  
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Table:26. Educational status and AgNOR score. 
Sl. 
No 
Education n 
AgNOR 95% 
CI of 
mean 
‘F’ P 
Significance 
between Mean SD 
1 Illiterate 55 4.8 1.9 4.3-5.3 
3
.0
3
1 
P
=
0
.0
53
 
All were Not 
Significant 
(NS) 
2 <10th Std 27 3.7 1.8 3.1-4.4 
3 10+ Std 18 4.2 2.0 3.3-5.2 
 Total 100 4.4 1.9 4.0-4.8 
  
Table 26 shows the relationship between education and AgNOR 
score. The results revealed that there was no significant relationship 
between them (P>0.05). 
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Table:27. Socio Economic status and AgNOR score. 
Sl. 
No 
SE status n 
AgNOR 95% 
CI of 
mean 
‘F’ P 
Significance 
between Mean SD 
1 <1000 63 4.7 1.9 4.2-5.2 
1
.7
5
7 
P
=
0
.1
78
 
All were Not 
Significant 
(NS) 
2 1000-1500 24 3.9 1.9 3.0-4.7 
3 1500-2000 13 4.2 1.6 3.2-5.2 
Total 100 4.4 1.9 4.0-4.8 
The Table 27 shows the relationship between Socio Economic 
status and AgNOR score. The results revealed that there was no 
significant relationship between them (P>0.05). 
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Table:28. Relation between Parity and AgNOR score. 
Sl. 
No P
a
ri
ty
 
n 
AgNOR 95% 
CI of 
mean 
‘F’ P 
Significance 
between 
Mea
n 
SD 
1 0 1 7.1 - - 
6
.2
8
5 
P
<
0.
00
1 
AgNOR Means of 
2&3, 3&4, 4&5 
were Not 
Significant. (P>0.05) 
All other AgNOR 
means between the 
parities were 
statistically 
significant. (P<0.05) 
2 2 34 3.5 1.7 2.9-4.0 
3 3 37 4.5 1.9 3.8-5.1 
4 4 22 5.1 1.7 4.3-5.8 
5 5 6 6.8 0.3 6.4-7.1 
 Total 100 4.4 1.9 4.0-4.8 
r=0.374 & P<0.001 
  
The above table 28 states the relationship between parity and 
AgNOR score. The age was increasing; the AgNOR score was also 
increasing. Both were positively significantly correlated. (r=0.374 and 
P<0.001).  
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Table:29. Relation between Duration of Married life and AgNOR 
score. 
Sl. 
No D
u
rn
 
(y
ea
rs
) 
n 
AgNOR 95% 
CI of 
mean 
‘F’ P Significance between 
Mean SD 
1 0-10 14 3.0 1.0 2.4-3.5 
1
0.
2
94
 
P
<
0.
0
01
 
AgNOR Means of 1&2, 
1&3,2&3, 3&4, 4&5 were Not 
Significant. (P>0.05). 
All other AgNOR means 
between the Md life were 
statistically significant. 
(P<0.05) 
2 10-20 24 3.5 1.6 2.9-4.0 
3 20-30 26 4.4 2.0 3.8-5.1 
4 30-40 26 5.4 1.8 4.6-6.1 
5 40-50 10 6.4 0.5 6.0-6.7 
 Total 100 4.4 1.9 4.0-4.8 
r=0.532 & P<0.001 
  
The above table 29 states the relationship between duration of 
married life and AgNOR score. The age was increasing; the AgNOR 
score was also increasing. Both were positively significantly correlated. 
(r=0.532 and P<0.001).  
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Table:30. Relation between Contraception and AgNOR score. 
Sl. 
No F
W
 
M
et
h
o
d
s 
n 
AgNOR 95% CI 
of 
mean 
F P Significance between 
Mean SD 
1 Nil 29 4.8 1.9 2.4-3.5 
2
.8
9
1 
P
=
0
.0
26
 
AgNOR Means of all 
except 1&3 were Not 
Significant. (P>0.05).  
AgNOR means of 1&3 
was statistically 
significant. (P<0.05) 
2 Barrier 3 3.0 0.2 2.9-4.0 
3 IUD 11 4.4 1.2 3.8-5.1 
4 OCP 2 4.8 2.9 4.6-6.1 
5 Perm 55 4.6 1.9 6.0-6.7 
 Total 100 4.4 1.9 4.0-4.8 
 
Table 30 shows the relationship between contraception and 
AgNOR score. The results revealed that there was no significant 
relationship between them except 1&3 (P>0.05).The AgNOR means 
between Nil and IUD were significantly differed (P<0.05). 
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The attributes such as multiple partners, previous screening, 
bleeding, white discharge, Both (bleeding & White discharge), S/E 
erosion and S/E growth were dichotomous. They were analyzed and 
interpreted according to their AgNOR score and the results are furnished 
in table 31. 
 
Table: 31. Relationships between the above attributes and AgNOR 
score. 
Attributes 
Yes 
of AgNOR 
Nil 
of AgNOR 
Differ 
b/w 
Means 
‘t’ df 
Signifi- 
cance 
Mean SD Mean SD 
Prev. 
screening 
4.8 1.9 4.4 1.9 0.4 0.578 98 
P=0.56
4 
Bleeding 
5.4 1.8 3.5 1.5 1.9 5.935 98 
P<0.00
1 
White 
discharge 
3.8 1.7 5.4 1.8 1.6 4.368 98 
P<0.00
1 
Bld +WD 
absent 
2.9 0.2 4.5 1.9 1.6 1.639 98 
P=0.10
4 
S/E erosion 
3.5 1.3 5.2 2.0 1.7 4.884 98 
P<0.00
1 
S/E growth 
6.5 0.8 3.5 1.5 3.0 
10.82
6 
98 
P<0.00
1 
S/E both 
absent 
3.3 1.8 4.7 1.8 1.4 3.148 98 
P=0.00
2 
  
86 
The AgNOR means of previous screening and not done were not 
statistically significant (P>0.05). The mean AgNOR score of bleeding 
subjects was significantly greater than the mean of the patients without 
bleeding (P<0.001). The mean AgNOR of patients with white discharge 
was significantly lesser than the mean AgNOR of women without white 
discharge (P<0.001). But the mean AgNOR of mothers without bleeding 
and white discharge and either of the complaint mothers mean AgNOR 
scores were not statistically significant (P>0.05). Similar observation was 
observed in the case of S/E erosion and growth. But the mean score of 
both S/E absent (3.3±1.8) was significantly lesser than the either of S/E 
present mean AgNOR score (4.7±1.8).  
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Table: 32. Relationship between HPE and AgNOR score. 
Sl HPE n 
AgNOR 95% 
CI of 
mean 
‘F’ P 
Significance 
between Mean SD 
1 Chr Cervix 45 2.8 0.4 2.7-2.9 
2
07
.3
 
P
<
0.
00
1 
AgNOR means of 
1&2,  1&3, 2&3, 
4&6, 4&7, 5&6, 
6&7 were not 
statistically 
significant. 
The other 
combinations  
Were statistically 
significant.  
2 Metaplasia 2 2.0 0.0 - 
3 Mild Dysplasia 8 2.8 0.2 2.7-3.0 
4 Mod dif.SCC 19 6.6 0.5 6.4-6.9 
5 Sev. Dysplasia 12 5.9 1.0 5.3-6.6 
6 Well.dif SCC 11 6.4 0.3 6.1-6.6 
7 Adeno CA 3 7.1 0.1 6.8-7.3 
 
Total 100 4.4 1.9 4.0-4.8 
88 
The table 32 relates the HPE and AgNOR. various HPE findings 
exhibit statistically significant difference in AgNOR values. chronic 
cervicitis, metaplasia and mild dysplasia cases have very low scores and 
the other cases have higher AgNOR scores. The highest score was present 
in adeno carcinoma followed by moderately differentiated and then well 
differentiated carcinoma. 
89 
DISCUSSION 
Invasive cancer of cervix is considered to be a preventable 
condition as there is an innumerable screening procedures to detect its 
preinvasive stage. 
A study was conducted in our gynnaec OPD and inpatient between 
the period from may 2013 to may 2014.women with symptoms of 
bleeding and profuse white discharge were screened. History in detail and 
thorough gynaecological examination was done. Cervical biopsy was 
taken from 100 patients and the sections were stained with conventional 
H & E stain to study the HPE and with silver stain to study AgNOR 
scores. AgNOR score was correlated with HPE report. 
Regarding age distribution, high incidence of chronic cervicitis was 
seen in the age group 30-40yrs.mild dysplasia was found to be more 
common between 30-40yrs.severe dysplasia was maximum in 40-
49yrs.moderately differentiated and well differentiated squamous cell 
carcinoma were maximum in 50-60yrs. 
Shiva raj et al in his study showed that mean age of patients with 
carcinoma was 54yrs.mean age for mild dysplasia was 42.5yrs.mean age 
for severe dysplasia was 44.2yrs. 
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Chronic cervicitis, dysplasia and malignancies were more 
commom among illiterates.55% of the women with abnormal cervical 
lesions were illiterates. This was attributed to lack of awareness of 
symptoms and inaccessibility of medical facilities. 
Chronic cervicitis, mild dysplasia were associated with low socio 
economic group. It is because of their poor personal hygiene, early age at 
first intercourse and they are less likely to screen for cervical cancer.40% 
of dysplasia and 85% of invasive cancer were seen in low income group. 
Regarding parity,our study showed increased incidence of 
dysplasia and invasive carcinomas among multiparous women.In patients 
with severe dysplasia,50% were P2,30% were P3,20% were P4 and 
above. 
Among patients with invasive cancer,3% were P2,43% were 
P3,54% were P2 and above. 
Misra et al also showed that women of high parity especially with 
higher age are more prone to progression to invasive cancer.Satija et al in 
2012 showed that women with 3 or > births showed 1.51 increased odds 
ratio to cancer cervix. 
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Regarding the duration of married life,it has  a distinct rolein the 
genesis of cervical dysplasia and carcinoma.In our study,incidence of 
dysplasia was 40% in women with marital life of 5-20yrs.Incidence of 
Squamous cell carcinoma was about 95%in patients with marital life 
>20yrs.Kustagi et al demonstated that increase in severity of cervical 
lesions increase with increase in the duration of sexual intercourse. 
International agency for research on cancer in 2002 concluded that 
use of OCPs for >10yrs increase the incidence of cervical cancer.In our 
study,13% of mild dysplasia used OCPs.5.2% of patients with moderately 
differentiated carcinoma gave history  of OCP usage. 
35% of patients with mild dysplasia used IUCD.55% of patients 
with mild dysplasia and severe dysplasia were permanently sterilized. 
 15% of patients with mild dysplasia and 30% of patients with 
severe dysplasia were not using any methods. 
        60% of patients with squamous cell carcinoma were 
permanently sterilized or non users of contraceptive methods.Since our 
study sample is small,we could not prove whether OCPs increase the 
incidence of cervical cancer.11% of women with post coital bleeding will 
present  with cervical cancer(shapley et al).45% of patients with  cervical 
cancer presents with bleeding per vaginum. 
92 
Early cervical cancer has no symptoms. Bleeding per vaginum, 
contact bleeding or profuse white discharge may be the presenting 
feature. The first symptom of cervical cancer is thin watery, blood tinged 
vaginal discharge(monk et al 2007). 
Study conducted by Gundrajkuppam et al in 2011 showed that 
white discharge was the most common complaint in >50% of patients 
with malignancy. In our study,50% of patients presented with complaints 
of white discharge,36% of patients with bleeding and 14% presents with 
both. 
In all the patients with bleeding, majority (35%) presented with 
moderately differentiated carcinoma. In all the patients with white 
discharge, majority of patients (60%) presented with chronic cervicitis. 
Both bleeding and white discharge also more common in 25% of patients 
with moderately differentiated SCC. 
       Shapley et al showed that 11% of women with postcoital 
bleeding will present with cervical cancer.In our study, 7% of patients 
had post coital bleeding. Among them, 42% of patients had chronic 
cervicitis,14% had mod. differentiated carcinoma, 28% had well 
differentiated carcinoma and 14% had severe dysplasia. 
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              Regarding the clinical appearance of cervix,the most common 
finding ws erosion in patients with chronic cervicitis(63.8%).60% of 
patients with mild dysplasia and 80% of patients with severe dysplasia 
presented with erosion cervix.90% of patients with invasive SCC and 
adenocarcinoma presented with a friable growth. 
 
              AgNOR is strictly related to the rapidity of cell proliferation. 
Therefore, AgNOR can be considered to represent a marker of cell 
proliferation rate.A number of studies carried out in different tumour 
types indicates the expression of AgNOR PROTEINS FOUND TO BE 
GREATER COMPARED TO NON MALIGNANT CELLS. Beningn 
cells tend to have a regular nucleolus with tight clustering of silver 
proteins and malignant cells show dispersal of NORs through the nucleus. 
 
Mean number of AgNORs per nucleus was significantly higher in 
dysplasia(mild-2.8 + 0.2,severe-5.9+1.0) and malignant lesions (well 
differentiated SCC 6.4+0.3,Mod sifferentiated SCC 6.6+0.5, 
Adenocarcinoma 7.1+0.1) as compared to metaplasia(2.0) and chroniuc 
cervicitis(2.8+0.4). 
 
All malignant lesions of cervix had significantly Higher AgNOR 
counts per nucleus compared to mild dysplasia. NOR counts were 
significantly higher in adenocarcinoma when compared to SCC. There 
 94 
 
was a significant difference observed between mean AgNOR counts of 
chronic cervicitis and dysplasia, mild and severe dysplasia, severe 
dysplasia and invasive SCC and adenocarcinoma. 
 
             Over all mean AgNOR counts were increasing from chronic 
cervicitis, dysplasia to carcinoma cervix. The following are the major 
significant AgNOR studies of similar interest which have been carried out 
in cervix.parallels have drawn between them and present study. 
 
        Singh u et al in 2006 found significant AgNOR scores in biopsy 
specimens.there was a definite increase in the AgNOR score with the 
progression of lesions i.e.,AgNOR count in CIN1(1.64), CIN2(2.68), 
CIN3(4.3). 
 
Shivarajet al in 2012,conducted a study which revealed that in 
cervical pathology, the number and shape of AgNOR dots change from 
benign to precancerous to malignant tumours. Mean AgNOR dots was 
1.55+0.165 in chronic cervicitis,1.73+0.257 in metaplasia,1.98+0.236 in 
mild dysplasia,2.97+0.38 in moderate dysplasia,4.05+0.411 in carcinoma 
respectively. 
 
According to the study carried out by shukla et al in 2013 on 50 
cervical smears, it was observed that the AgNOR counts in cervical 
lesions gradually increases with the severity of the lesions i.e, from a 
95 
normal cervix to chronic cervicitis to dysplasia to carcinoma which has 
the highest score. 
Kaushik et al in 2003 carried out a study on cervical biopsies 
which included 100 cases and categorized them as cervicitis, CIN1, 
CIN2, CIN3, CA CERVIX. All of the categories in this study showed 
significant variations in the AgNOR counts(p<0.001). 
Misra JS et al in 2005, conducted a study on 50 cases of cervical 
smears.In the normal and inflammatory smears ,AgNOR dots ranged 
from 1-2,LSIL dots ranged from 2-4,HSIL dots 6-8,frank SCC had 10 
dots. 
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Prathiba Kuruvilla 
1995 
- - 1.8 3 4.3 - - 
Rowlands 1998 - - 2.2 2.8 - - - 
Kaushik 1999 2.3 - 3.8 5.1 - 6.4 6.7 
Misra 2005 1-2 - 2-4 6-8 8-10 - - 
Singh et al 2006 - - 
1.64 - 
2.68 
4.3 - - - 
Shivaraj et al 2012 
1.5+ 
0.165 
1.73 + 
0.257 
1.98 + 
0.236 
2.97 + 
0.387 
4.05 + 
0.411 
- - 
Sukla et al 2013 2.09 - 2.8 4.17 5.9 - - 
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SUMMARY 
 
 35% of women with chronic cervicitis, 100% of women with 
metaplasia, 60% of women with mild dysplasia are in the age 
group 30-39yrs. 
 50% of women with severe dysplasia are in the age group of 40-
49yrs.70% of women with well differentiated SCC are in the age 
group of 50-69yrs.65% of women with mod. Differentiated SCC 
are in the age group of 50-59yrs.70% of adenocarcinoma are in the 
age group of 40-49yrs. 
 Distribution of cervical cancer was not affected by educational 
status. 
 55% of chronic cervicitis,40% of dysplasia,80% of carcinoma 
cervix were reported among low income group. 
 Chronic cervicitis, metaplasia, dysplasia were common among P2, 
where as mod. diff, well diff, adeno carcinoma were common 
among p3 and above. 
 77% of chronic cervicitis, 85% ofdysplasia and 100% of carcinoma 
were seen in patients with more than 5yrs of sexual life. 
 
98 
 Adeno CA and chronic cervicitis not associated with OCP
usage.only 13% of patients with mild dysplasia and 5.2% of
patients with mod diff CA gave H/O OCP usage.
 80% of patients with chronic cervicitis, 70% of patients with
dysplasia and 24% of patients with carcinoma presented with white
discharge.
 24% of patients with chronic cervicitis, 30% of patients with
dysplasia,80% of patients with carcinoma presented with bleeding.
 White discharge was the major complaint among the women with
chronic cervicitis.bleeding per vaginum was the major complaint
among the women with carcinoma cervix.
 64% of chronic cervicitis,60% of mild dysplasia and 80% of
patients with severe dysplasia showed erosion cervix on per
speculum examination.
 90% of patients with invasive cancer presented with friable growth.
 As the age increases,AgNOR score also increases.
 Educational status and socioeconomic status are not significantly
rekated to AgNOR score.
 As the parity increases AgNOR score also increases.
99 
 Patients with longer duration of married life have higher AgNOR
score than recently married.
 Patients with bleeding have higher AgNOR score (5.4) than those
with white discharge.
 Patients with growth on per speculum examination have higher
AgNOR score (6.5%) than those with erosion.
 Higher score was seen in  adeno CA (7.1+0.1) followed by mod
diff CA(6.6+0.5) and then well diff CA (6.4+0.3)
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CONCLUSION 
 
 Screening has reduced deaths from cervical cancer. It is the only 
cancer where we can find it early and treat it .hence earlier 
diagnosis in adult women is a desirable goal. 
 
 In our present study, mean AgNOR counts in cervical epithelium 
showed a progressive and statistically significant increase from 
chronic cervicitis, dysplasia, SCC and adeno CA.As the 
proliferative capacity of the lesion increases, the malignant 
potential of the lesion also increases. Hence AgNOR scoring can 
be used as a reliable indicator of cell proliferation, in turn 
malignant potential of a lesion. 
 
 This study underscored the diagnostic potential of AgNOR counts 
especially in delineating between dysplasia and invasive cancer 
cervix. It is simple, easy to perform, inexpensive and reliable 
proliferative marker in identifying different grades of cervical 
lesion. 
 
 It has got prognostic significance also.CIN lesions with low 
AgNOR count are more likely to regress in comparison to CIN 
lesions with high AgNOR counts 
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 Our study indicates that AgNOR technique can be used as an
adjunct to routine histopathological examination of lesions of the
cervix especially in dysplasia. Eventhough more studies are
necessary, our preliminary study indicates the diagnostic
importance of AgNOR counts in cervical lesions and other lesions
of cervix.
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PROFORMA 
Serial No. : Name : 
IP/ OP No. : Age : 
Income : Education : 
I. Complaints 
1. Bleeding PV
Post coital bleeding
Continuous  / Intermittent
Intermenstrual
Post menopausal
Associated pain
2. Vaginal Discharge
Duration
Quantity
Colour
Foul smell
Pruritis
3. Lower abdominal pain
4. Urinary symptoms
5. Bowel symptoms
6. Loss of weight
7. Loss of appetite
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II. Personal History 
 Diet 
 Hygiene 
III. Menstrual History 
 Age at menarche 
 Cycles 
 LMP 
 Age at menopause 
IV. Married since 
V. Sexual promiscuity 
 Multiple sexual partners 
 History of STD 
 Husband 
 Wife 
VI. Obstetrical History 
 P L A 
 LCB  
 Contraception  
 Barrier 
 OCP 
 IUCD 
 Permanent 
 Nil 
112 
VII. General  Examination
Built Thyroid 
Anaemia Breast 
Pedal edema BP 
Lymphadenopathy PR 
CVS RS 
VIII. Per abdomen
IX. Local examination of Genitalia
 Normal 
 Abnormal 
X. Speculum Examination 
 Cervix 
 Vagina 
XI. Per vaginal examination
XII. P/R
XIII. Biopsy
XIV. AgNOR count
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KEY TO MASTER CHART  
 
S.E. Status   - Socio Economic Status  
OCP    - Oral Contraceptive Pill 
Perm    - Permanent  
PC    - Postcoital Bleeding  
PMB   - Post Menopausal Bleeding  
IMB   - Inter Menstrual Bleeding  
Chr. cervicitis  - Chronic cervicitis  
CA   - Carcinoma  
SCC   - Squamous Cell Carcinoma  
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MASTER CHART 
S.No. I.P.No Age Education  
S.E. 
Status 
Parity 
Duration 
of 
Married 
Life  
Multiple 
Partners  
Contraception Bleeding  
White 
Discharge 
H/O 
STD 
Prev 
Screening 
S/E 
HPE 
Agnor 
Count Erosion Growth 
1 51812 40 Nil <1000 3 >20 Nil Perm Nil Yes Nil Nil Yes Nil Chr cervicitis 2.5 
2 55261 34 <10 Std 
1001-
1500 
2 11-20 Nil Perm Nil Yes Nil Nil Yes Nil 
Mild 
Dysplasia 
3.1 
3 55387 53 Iliterate <1000 3 >20 Nil Nil PMB Yes Nil Nil Nil Yes 
Mod diff 
SCC 
6.9 
4 56718 34 <10 Std <1000 3 5-10 Nil Perm Nil Yes Nil Nil Yes Nil Chr cervicitis 3.08 
5 58047 60 Iliterate <1000 4 >20 Nil Nil PMB Nil Nil Nil Nil Yes 
Mod diff 
SCC 
7.2 
6 59479 60 Iliterate <1000 4 >20 Nil Perm PMB Nil Nil Nil Nil Yes 
Well diff 
SCC 
6.3 
7 60635 50 Iliterate <1000 4 >20 Nil Perm PMB Yes Nil Nil Nil Yes 
Mod diff 
SCC 
5.6 
8 68530 31 < 10 Std 
1001-
1500 
2 5-10 Nil Perm Nil Yes Nil Nil Yes Nil Chr cervicitis 1.8 
9 58088 55 Nil <1000 3 >20 Nil IUCD PMB Nil Nil Nil Yes Nil Chr cervicitis 2.3 
10 60525 60 Nil <1000 4 >20 Nil Nil PMB Nil Nil Nil Nil Yes 
Mod diff 
SCC 
6.8 
11 59796 25 <10 Std 
1001-
1500 
2 5-10 Nil Barrior Nil Yes Nil Nil Yes Nil Chr cervicitis 2.9 
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12 64724 56 <10 Std <1000 4 or > >20 Nil Perm PMB Nil Nil Nil Nil Yes Adeno CA 7.1 
13 64695 43 <10 Std 
1500-
2000 
3 15-20 Nil Perm IMB Yes Nil Nil Yes Nil 
Severe 
dysplasia 
5.8 
14 64706 30 Nil <1000 2 5-10 Nil Barrior PC Yes Nil Nil Yes Nil Chr cervicitis 3.2 
15 64011 48 >10 Std <1000 3 >20 Nil Perm Nil Yes Nil Nil Yes Nil Chr cervicitis 3.3 
16 65135 52 >10 Std 
1500-
200 
3 >20 Nil Perm PMB Nil Nil Nil Nil Yes 
Mod diff 
SCC 
6.1 
17 68058 46 Nil <1000 3 >20 Nil Nil Nil Yes Nil Nil Yes Nil Chr cervicitis 1.8 
18 65718 54 Nil <1000 2 >20 Nil Perm PMB Yes Nil Nil Nil Nil Chr cervicitis 2.2 
19 66632 44 < 10 Std 
1001-
1500 
4 >20 Nil Nil Nil Nil Nil Nil Nil Yes Chr cervicitis 2.9 
20 68078 60 Nil <1000 4 >20 Nil Perm PMB Nil Nil Nil Yes Nil 
Mod diff 
SCC 
6.6 
21 71007 49 >10 
1001-
1500 
3 >20 Nil Perm Nil Yes Nil Nil Yes Nil 
Severe 
dysplasia 
5.6 
22 73435 59 <10 <1000 4 >20 Nil Perm Nil Yes Nil Nil Yes Nil Chr cervicitis 3.0 
23 74678 32 <10 
1001-
1500 
3 5-10 Nil Perm Nil Yes Nil Nil Yes Nil Chr cervicitis 2.8 
24 74696 36 >10 <1000 2 15-20 Nil Perm Nil Yes Nil Nil Yes Nil Chr cervicitis 2.6 
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25 79166 24 Nil 
100-
1500 
2 5-10 Nil IUCD Nil Yes Nil Nil Nil Nil Chr cervicitis 1.5 
26 76576 51 Nil <1000 3 >20 Nil Perm Nil Yes Nil Nil Nil Yes 
Mod diff 
SCC 
6.8 
27 78388 60 Nil <1000 4 >20 Nil Perm Nil Yes Nil Nil Yes Nil Chr cervicitis 2.9 
28 77428 56 <10 
1001-
1500 
3 >20 Nil Nil Yes Yes Nil Nil Nil Yes 
Mod diff 
SCC 
6.8 
29 77329 45 Nil <1000 3 >20 Nil Perm IMB Yes Nil Nil Yes Nil 
Mild 
Dysplasia 
3 
30 72148 36 <10 
1500-
2000 
4 11-20 Nil IUCD PC Nil Nil Nil Yes Nil Chr cervicitis 2.5 
31 62927 56 Nil <1000 4 >20 Nil Nil PMB Nil Nil Nil Nil Yes 
Mod diff 
SCC 
5.8 
32 68865 54 Nil <1000 5 >20 Nil Nil PMB Nil Nil Nil Nil Yes 
Mod diff 
SCC 
6.9 
33 68516 52 >10 
1500-
2000 
2 >20 Nil Perm Nil Yes Nil Yes Yes Nil 
Severe 
dysplasia 
5.8 
34 68388 50 <10 
1001-
1500 
4 >20 Nil Perm Nil Yes Nil Nil Yes Nil Chr cervicitis 2.9 
35 76607 59 Nil <1000 3 >20 Nil Nil PMB Nil Nil Yes Nil Yes 
Well diff 
SCC 
5.9 
36 72308 42 Nil <1000 3 11-20 Nil Perm Nil Yes Nil Nil Nil Nil Chr cervicitis 2.6 
37 79235 46 Nil 
1001-
1500 
2 >20 Nil Nil Nil Yes Nil Nil Nil Nil 
Severe 
dysplasia 
5.3 
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38 68817 52 Nil <1000 3 >20 Nil Perm PMB Yes Nil Nil Yes Nil Chr cervicitis 2.9 
39 68900 47 <10 <1000 3 >20 Nil Perm Nil Yes Nil Nil Yes Nil Chr cervicitis 3.1 
40 76822 49 >10 
1001-
1500 
3 >20 Nil Perm Nil Yes Nil Yes Yes Nil Chr cervicitis 2.8 
41 76814 35 <10 
1001-
1500 
2 11-20 Nil Perm Nil Yes Nil Nil Yes Nil Metaplasia 2 
42 78312 48 Nil <1000 3 >20 Nil Nil IMB Nil Nil Nil Nil Yes Adeno CA 7.2 
43 73250 48 <10 <1000 3 >20 Nil Nil Nil Nil Nil Nil Nil Nil 
Mild 
Dysplasia 
2.7 
44 75755 36 >10 
1001-
1500 
2 11-20 Nil Perm PC Nil Nil Nil Nil + 
Mod diff 
SCC 
7.0 
45 77570 43 Nil <1000 3 >20 Nil Nil - Yes Nil Nil + - Chr cervicitis 2.8 
46 76812 30 >10 
1500-
2000 
2 5-10 Nil IUCD Nil Yes Nil Nil Nil Nil Chr cervicitis 1.9 
47 77164 35 Nil <1000 2 5-10 Nil Perm IMB Nil Nil Nil Yes Nil Chr cervicitis 2.9 
48 75720 39 <10 <1000 3 11-20 Nil Perm IMB Nil Nil Nil Nil Nil Chr cervicitis 2.5 
49 75663 37 Nil <1000 2 11-20 Nil Nil Nil Yes Nil Nil Nil Nil Metaplasia 2 
50 71076 40 Nil <1000 4 >20 Nil Perm PMB Nil Nil Nil Nil Yes 
Well diff 
SCC 
5.8 
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51 74679 37 >10 
1500-
2000 
2 11-20 Nil Perm Nil Yes Nil Yes Nil Nil Chr cervicitis 3.0 
52 76968 60 Nil <1000 4 >20 Nil Perm PMB Yes Nil Nil Nil Yes 
Mod diff 
SCC 
6.2 
53 74054 45 Nil <1000 3 >20 Nil Nil Nil Yes Nil Nil Yes Nil Chr cervicitis 3.5 
54 76944 55 Yes <1000 3 >20 Nil IUCD IMB Nil Nil Nil Nil Yes 
Well diff 
SCC 
6.3 
55 74787 34 >10 
1001-
1500 
2 11-20 Nil Nil Nil Yes Nil Nil Nil Nil Chr cervicitis 3.2 
56 73543 40 <10 
1001-
1500 
2 5-10 Nil Perm IMB Nil Nil Nil Yes Nil Chr cervicitis 2.8 
57 73558 40 Nil <1000 4 >20 Nil Perm Nil Yes Nil Nil Yes Nil 
Mild 
Dysplasia 
2.9 
58 73558 50 Nil <1000 3 >20 Nil Nil Nil Yes Nil Nil Nil Nil Chr cervicitis 2.8 
59 73082 50 Nil <1000 3 >20 Nil Perm PMB Nil Nil Nil Nil Yes 
Mod diff 
SCC 
6.9 
60 73102 35 >10 
1500-
2000 
2 5-10 Nil Perm Nil Yes Nil Nil Nil Nil Chr cervicitis 3.0 
61 70936 42 Nil <1000 3 >20 Nil Perm Nil Yes Nil Yes Yes Nil Chr cervicitis 2.8 
62 75923 40 <10 
1001-
1500 
3 >20 Nil Nil Nil Yes Nil Nil Yes Nil Chr cervicitis 2.9 
63 73041 35 <10 <1000 2 5-10 Nil IUCD Nil Yes Nil Nil Yes Nil 
Mild 
Dysplasia 
2.5 
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64 76688 39 Nil <1000 2 11-20 Nil Nil PC Nil Nil Nil Yes Nil 
Severe 
dysplasia 
5.8 
65 78952 27 <10 
1001-
1500 
2 5-10 Nil Nil Yes Nil Nil Nil Nil Nil Chr cervicitis 2.9 
66 72284 34 Nil <1000 2 5-10 Nil IUCD Nil Yes Nil Nil Nil Nil 
Mild 
Dysplasia 
2.7 
67 79983 60 Nil <1000 4 >20 Nil OCP PMB Nil Nil Nil Nil Yes 
Mod diff 
SCC 
6.9 
68 79629 40 >10 <1000 3 11-20 Nil Perm Nil Yes Nil Nil Yes Nil Chr cervicitis 2.9 
69 79720 39 Nil <1000 3 11-20 Nil Perm IMB Yes Nil Nil Yes Nil Chr cervicitis 2.7 
70 77678 50 Nil <1000 4 >20 Nil Nil Nil Yes Nil Nil Yes Nil 
Severe 
dysplasia 
5.8 
71 78182 47 Yes >1000 3 >20 Nil Perm PMB Nil Nil Nil Nil Yes 
Well diff 
SCC 
6.4 
72 78232 48 <10 
1001-
1500 
2 >20 Nil Nil PMB Nil Nil Nil Yes Nil 
Severe 
dysplasia 
5.7 
73 78234 60 Nil <1000 3 >20 Nil Perm PMB Nil Nil Nil Nil Yes 
Well diff 
SCC 
6.3 
74 78033 53 Nil <1000 4 >20 Nil Perm PMB Nil Nil Nil Nil Yes 
Well diff 
SCC 
6.7 
75 79147 40 >10 <1000 2 11-20 Nil Perm PC Nil Nil Nil Yes Nil Chr cervicitis 2.9 
76 70854 60 Nil <1000 5 >20 Nil Nil PMB Nil Nil Nil Nil Yes 
Well diff 
SCC 
6.3 
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77 70675 33 >10 >1500 2 5-10 Nil Perm Nil Yes Nil Nil Yes Nil 
Severe 
dysplasia 
5.8 
78 70856 40 Nil <1000 3 11-20 Nil Perm Nil Yes Nil Nil Nil Nil Adeno CA 7.0 
79 70241 57 <10 <1000 3 >20 Nil Nil PMB Yes Nil Nil Nil Yes 
Well diff 
SCC 
6.9 
80 70529 55 Nil <1000 4 >20 Nil Nil PMB Nil Nil Nil Nil Yes 
Mod diff 
SCC 
6.0 
81 70805 60 Nil <1000 4 >20 Nil Perm PMB Nil Nil Nil Yes Nil 
Severe 
dysplasia 
5.4 
82 70795 36 >10 
1500-
200 
2 11-20 Nil IUCD Nil Nil Nil Nil Yes Nil 
Mild 
Dysplasia 
2.8 
83 73001 53 Nil <1000 5 >20 Nil Perm PMB Nil Nil Nil Nil Yes 
Mod diff 
SCC 
7.0 
84 73556 24 <`0 
1500-
2000 
2 5-10 Nil Nil Nil Yes Nil Nil Yes Nil Chr cervicitis 3.2 
85 75128 58 Nil <1000 4 >20 Nil Nil Nil Yes Nil Nil Nil Nil Chr cervicitis 3.4 
86 74050 33 Nil 
1001-
1500 
2 5-10 Nil Barrior Nil Yes Nil Nil Nil Nil Chr cervicitis 2.9 
87 74092 60 Nil <1000 5 >20 Nil Perm PC Nil Nil Yes Nil Yes 
Well diff 
SCC 
6.4 
88 71186 34 <10 
1001-
1500 
2 11-20 Nil IUCD Nil Nil Nil Nil Yes Nil Chr cervicitis 3.2 
89 75080 37 >10 
1001-
1500 
2 11-20 Nil Perm Nil Yes Nil Nil Nil Nil Sq.Metaplasia 9.2 
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90 79090 38 Nil <1000 4 >20 Nil Perm PC Nil Nil Nil Nil Yes 
Well diff 
SCC 
6.6 
91 79141 50 Nil <1000 5 >20 Yes Nil PMB Yes Nil Yes Nil Yes 
Mod diff 
SCC 
7.1 
92 79524 35 >10 
1500-
2000 
2 5-10 Nil IUCD Nil Yes Nil Nil Nil Nil Chr cervicitis 2.9 
93 79526 50 Nil <1000 3 >20 Nil Perm PMB Nil Nil Nil Nil Yes 
Mod diff 
SCC 
7.1 
94 79743 24 <10 
1000-
1500 
2 >20 Nil Perm Nil Yes Nil Nil Yes Nil Chr cervicitis 3.3 
95 79165 55 Iliterate <1000 4 >20 Nil Nil PMB Yes Nil Nil Yes Nil Chr cervicitis 3.4 
96 78035 42 >10 
1500-
2000 
3 15-20 Nil Perm Nil Yes Nil Nil Yes Nil 
Severe 
dysplasia 
5.8 
97 78016 35 Nil <1000 2 5-10 Nil IUCD Nil Yes Nil Nil Nil Nil Chr cervicitis 2.9 
98 75918 49 Nil 
1500-
2000 
3 >20 Nil Perm Nil Yes Nil Nil Yes Nil 
Severe 
dysplasia 
5.8 
99 75082 55 Nil <1000 5 >20 Nil Perm PMB Nil Nil Nil Nil Yes 
Mod diff 
SCC 
6.9 
100 76985 30 Nil 
1001-
1500 
2 5-10 Nil OCPS Yes Nil Nil Nil Nil Nil 
Mild 
Dysplasia 
2.8 
